RCKTHealthcare · BiotechnologyThe 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +198.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (82): Sales and profits are climbing, and climbing faster than before.
Momentum (37): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +198.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | Chardan Capital | Maintains | Buy | $11 |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | $16 → $15 |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | $11 |
| 30 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Mar 2026 | Goldman Sachs | Maintains | Sell | — |
| 27 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 18 Nov 2025 | B of A Securities | Maintains | Buy | — |
| 18 Nov 2025 | JP Morgan | Downgrade | Underweight | — |
| 14 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 3 Oct 2025 | Leerink Partners | Maintains | Market Perform | — |
| 20 Aug 2025 | B of A Securities | Upgrade | Buy | — |
| 20 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 8 Aug 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 25 July 2025 | B of A Securities | Downgrade | Neutral | — |
| 25 July 2025 | Canaccord Genuity | Maintains | Buy | — |
| 24 July 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCKT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Rocket Pharmaceuticals, Inc. returned +2.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 73% of US stocks
Cheaper than 64% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 39% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rocket Pharmaceuticals, Inc. has a market value of $367.7M and an enterprise value of $108.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.3M.
Diluted earnings per share, trailing twelve months: $−0.17.
Free cash flow in the twelve months to 30 June 2026: −$170.4M.
Trailing P/E: −1.7×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Rocket Pharmaceuticals, Inc. employs 202 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago, and its stock has risen 6% since that report. The article examines whether the stock can sustain this upward momentum going forward.
Why it matters — RCKT watchers would care because the piece evaluates the stock's recent post-earnings performance and outlook.
Rocket Pharmaceuticals announced it will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York. CEO Gaurav Shah, M.D., will take part in fireside chats at these events.
Why it matters — A Rocket Pharmaceuticals watcher would be interested because these conference appearances give the CEO an opportunity to present the company's genetic medicines pipeline and cardiovascular disease programs to the investment community.
Rocket Pharmaceuticals recorded earnings growth in the second quarter. Kresladi launch preparations are advancing, and safety findings for RP-A501 support its next development steps.
Why it matters — A RCKT watcher would care because the quarterly earnings growth and continued progress on both the Kresladi launch and the RP-A501 program reflect ongoing advancement across the company's pipeline.
Rocket Pharmaceuticals reported its financial results and recent operational progress for the second quarter ended June 30, 2026. The company highlighted the approval of KRESLADI, which it said materially strengthened its position and demonstrated its ability to advance a genetic medicine.
Why it matters — RCKT watchers would care because the KRESLADI approval signals significant progress for the company's genetic medicines pipeline and its commercial-stage status.
Rocket Pharmaceuticals shared a clinical safety update regarding the first three patients treated in its global, pivotal Phase 2 trial for Danon disease. The update was presented as positive early safety data from the revised genetic therapy trial.
Why it matters — RCKT watchers would care because early safety results from the pivotal Phase 2 Danon disease trial are a key data point for the company's lead genetic therapy program.
The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 6 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 55 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Rocket Pharmaceuticals, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +198.5% from the last close, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 55 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.
Rocket Pharmaceuticals, Inc. returned +2.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology.
The most recent item we track (Zacks Investment Research, 9 Sept 2026): "Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?". Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago, and its stock has risen 6% since that report. The article examines whether the stock can sustain this upward momentum going forward.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.
CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com
